A First for Hypoparathyroidism — Yorvipath (Palopegteriparatide) Earns FDA Nod

Yorvipath (palopegteriparatide; TransCon PTH) has been approved to treat hypoparathyroidism, a rare endocrine disorder affecting 70,000 to 90,000 people in the US. Yorvipath, developed using Ascendis Pharma’s TransCon technology, is the first and only approved treatment for hypoparathyroidism, marking this approval as a major milestone.